Biotech Firms Develop New Measles Treatments as US Cases Surge

Biotech companies and academic research groups have begun developing medical treatments for measles as U.S. cases hit a 35-year high, according to Ars Technica. These countermeasures aim to provide options for infected patients and vulnerable individuals requiring short-term protection, filling a gap created by declining vaccination rates.

The shift toward treatment development follows a period where high vaccination efficacy removed the financial and medical incentives to create therapeutics. However, recent outbreaks in Utah and South Carolina have accelerated the need for clinical alternatives, Ars Technica reports.

Measles Case Surge in 2025

The United States has seen a sharp increase in measles infections during 2025.

This surge represents a significant escalation compared to 2024, which recorded only 285 cases in total, per the same report. The current spike is attributed to declining vaccination rates across the country.

Biotech Development and Implementation Timelines

The current effort to develop measles treatments is being led by a mix of academic groups and biotechnology firms. These entities are focusing on two primary needs: treating those already infected with the virus and providing short-term protection for individuals who cannot be vaccinated.

Despite the urgency of the outbreaks, these treatments are not immediately available. Ars Technica reports that it will likely be years before these countermeasures reach the public.

There is also significant uncertainty regarding the adoption of these treatments. Researchers and biotech firms face a question of whether individuals who refuse standard vaccines would be willing to accept pharmaceutical treatments after infection occurs.